Pharmaceutical Formulations

Ken Olsen is a protein and computational chemist at Loyola University Chicago. His experimental laboratory studies the development of hemoglobin-based blood substitutes, protein-based drug delivery systems and targeted photodynamic therapy. His computational laboratory studies the effects of mutations on protein structure, design of new antibiotics and drug-excipient interactions.

Dr. Vladimir Torchilin graduated from the Moscow University with MS in Chemistry, and also obtained there his Ph.D. (1971) and D.Sc. (1981) in Polymer Chemistry, Chemical Kinetics and Catalysis, and Chemistry of Physiologically Active Compounds. In years 1968-1973 Dr. Torchilin made his research at the Chemical Department of Moscow State University. In 1974-1990 he was with the Institute of Experimental Cardiology, Russian Cardiology Research Center, where he founded the Laboratory of Enzyme Engineering of which he was a Head in 1981-1990. In 1991 Dr. Torchilin joined Massachusetts General Hospital and Harvard Medical School as the Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. Since 1998 Dr. Torchilin is with Northeastern University. In 1998-2008 he served as a Distinguished Professor and Chairman of the Department of Pharmaceutical Sciences. Since 2005, he is also the Director of The Center for Pharmaceutical Biotechnology and Nanomedicine.

His research interests have focused on the engineering of biomedical polymers and polymeric drugs, medicinal enzyme stabilization and immobilization, drug delivery and targeting, drug carriers including liposomes and micelles, long-circulating drug carriers, novel imaging agents, antibody modification, and, more recently, experimental cancer immunology. His outstanding contributions to all these areas are widely recognized by the international scientific community. Related research has been communicated in more than 400 original publications. He also wrote more than 150 reviews and book chapters, wrote and edited 12 books including "Immobilized Enzymes in Medicine", "Handbook of Targeted Delivery of Imaging Agents", “Liposomes: A Practical Approach”, “Biomedical Aspects of Drug Targeting”, “Delivery of Protein and Peptide Drugs in Cancer”, “Nanoparticulates as Drug Carriers”, “Multifunctional Pharmaceutical Nanocarriers”, and 4 volume set “Handbook of Nanobiomedical Research”, made over 250 invited lectures and seminars and holds more than 40 patents. He is also a Co-Editor of a novel book series on Biomedical Nanotechnology with Pan Stanford Publishing (World Scientific). According to Google Scholar, his H-index is 97 with >47,000 citations. His commitment to the engineering of drug delivery and targeting systems is also reflected in the numerous grants and contracts awarded to him by the NIH and various industries.

Roger M Leblanc received his B.S. in chemistry in 1964 from Université Laval, Canada, and Ph. D. in physical chemistry in 1968 from the same university. From 1968 to 1970, he was a postdoctoral fellow in the laboratory of Prof. George Porter, FRS, in Davy Faraday Research Lab, the Royal Institution of Great Britain. He was a professor from 1970 to 1993 at Department of Chemistry and Biology in Université du Quebec ii Trois Riviéres, Canada. During this period, he was Chair from 1971 to 1975 at the same department, and Director from 1981 to 1991 at Photobiophysics Research Center. In 1994, he moved to University of Miami, where he has been a professor at Department of Chemistry since then to present. At University of Miami, he was Chair of Department of Chemistry from 1994 to 2002, and he is appointed as Chair from 2013 to present. He was also one of the three editors of Colloids and Surfaces B: Biointerfaces from 1998 to 2017. During his early career as a scientist, his research interest was on the photosynthesis and photoconductivity using surface chemistry and spectroscopy. His current research interest is to apply 2-dimensional (2-D) surface chemistry combined with spectroscopy and microscopy to investigate the properties of nanomaterials (carbon dots, graphene oxide and quantum dots) and the fibrillation process of amyloidogenic proteins (insulin, amyloid-beta peptide and islet amyloid polypeptide). He is also interested to design and develop biosensors with high sensitivity and selectivity for diseases diagnosis. He has published 512 scientific articles in peer-reviewed journals. As a professor, he has supervised more than 100 master and Ph.D. students.

During his early career as a scientist, his research interest was on the photosynthesis and photoconductivity using surface chemistry and spectroscopy. His current research interest is to apply 2-dimensional (2-D) surface chemistry combined with spectroscopy and microscopy to investigate the properties of nanomaterials (carbon dots, graphene oxide and quantum dots) and the fibrillation process of amyloidogenic proteins (insulin, amyloid-beta peptide and islet amyloid polypeptide). He is also interested to design and develop biosensors with high sensitivity and selectivity for diseases diagnosis.

Nagatoshi Nishiwaki received his Ph.D. from Osaka University in 1991. He worked at Osaka Kyoiku University (1991–2008). From 2000 to 2001, he joined Karl Anker Jørgensen’s group at Aarhus University, Denmark. Between 2008 and 2009 he worked at Anan National College of Technology. He then moved to the School of Environmental Science and Engineering, Kochi University of Technology, in 2009, and he became a professor in 2011. His research interests comprise synthetic organic chemistry using nitro compounds, heterocycles (ring transformations, 1,3-dipolar cycloadditions etc.), and pseudo- intramolecular reactions. He has more than 120 papers and 20 review articles.

His research interests comprise synthetic organic chemistry using nitro compounds, heterocycles (ring transformations, 1,3-dipolar cycloadditions etc.), and pseudo- intramolecular reactions

Jacob O. Midiwo attained a BSc degree at the University of Nairobi while his PhD training was at the University of Maryland at College Park, USA. He has been a lecturer in Organic Chemistry at the Department of Chemistry, University of Nairobi since 1981. Prof. Midiwo has been involved in Phytochemistry research for more than three decades in Nairobi. The families of plants he has studied in some detail include Polygonaceae, Myrsinaceae, Compositae, Papilionaceae and other isolated genera and species. A particular area of interest is the study of plants with aerial flavonoid / terpenoid surface exudates: their biogenetic origin and potential application.

Organic Chemistry, Phytochemistry.

The author received an honorable PhD in mathematics and majored in engineering at MIT. He attended different universities over 17 years and studied seven academic disciplines. He has spent 20,000 hours in T2D research. First, he studied six metabolic diseases and food nutrition during 2010-2013, then conducted research during 2014-2018. His approach is “math-physics and quantitative medicine” based on mathematics, physics, engineering modeling, signal processing, computer science, big data analytics, statistics, machine learning, and AI. His main focus is on preventive medicine using prediction tools. He believes that the better the prediction, the more control you have.

The author spent seven years and 18,000 hours to study, analyze and research his chronic disease conditions. Here is the comparison between 2010 and 2017: Weight: 205 / 172 lbs. Waistline: 44 / 34 inches PPG: 350 / 116 mg/dL FPG: 185 / 119 mg/dL Daily glucose: 280 / 117 mg/dL A1C: 10.0 / 6.1 % ACR: 116 / 12 mg/mmol Triglycerides: 1161 / 69 mg/dL He used mathematics, physics, engineering modeling, and computer science (big data analytics and AI) to derive the mathematical metabolism model and three prediction tools for weight, FPG, and PPG with >30 input elements. This study includes 11 categories: weight, glucose, blood pressure, lipids, food, water, exercise, sleep, stress, life pattern regularity, time, with ~500 input and output elements.

Dr Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980. Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences, National Center for Immunology (Russia), NIH, Bethesda, USA, and British Society for Immunology to cover 4 British university facilities.

A Researcher-immunologist.

Jean-Michel Scherrmann, Pharm. D., Ph. D. is professor in the department of Pharmacokinetics, Faculty of Pharmacy, the University Paris Descartes. He has led the Neuropsychopharmacology Unit at the French Institute of Health and Medical Research (INSERM) and the National Center of Scientific Research (CNRS) from 2002 to 2013. He has been recently promoted Dean of the Faculty of Pharmacy at University Paris Descartes and nominated Professor at the National Institute of Nuclear Sciences and Techniques.

Pharmacokinetics, neuropharmacokinetics, Pharmacology & Toxicology, Neuroscience & Behavior

Ke-He Ruan is Professor of Medicinal Chemistry & Pharmacology and he is Director for Center for Experimental Therapeutics and Pharmacoinformatics (CETP)

Signaling Molecules and Drugs, Drug targets, Molecular Mechanisms, Biomedical field

Adalberto Rezende Santos is Ph.D in Cellular and Molecular Biology from Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. Actually, he is a Senior Investigator and Head of the Laboratory of Molecular Biology Applied to Mycobacteria of Oswaldo Cruz Institute, Supervisor at the post-graduation programs of Cellular, Molecular Biology, and Clinical Medicine from Fiocruz and Federal University of Rio de Janeiro respectively. He is ad hoc consultant of the Executive Secretariat of Science Technology and Environment and of the Ministry of Health, Brazil. He is also referee of the Journal of Infectious Diseases and Pharmacogenomics.

Pharmacogenomics, Drug discovery

Dr. Mostafa Norizadeh Tazehkand from Iran (Mioandoab-Qushachay) is currently working as an Assistant Professor in Pharmaceutical Biotechnology department, Bulent Ecevit University, Zonguldak, Turkey. He completed his B.Sc. in Molecular and Cell Biology at Tonekabon University, Iran. Later in 2012, he graduated with M.Sc. in Biotechnology at Cukurova University, Turkey. Dr. Mostafa did his PhD. in Biotechnology at Cukurova University, Turkey in the year 2016. He has published several papers (More than 30) in reputed journals and has participated in several international conferences. He is working as an editorial member in almost 35 scientific journals. His research interests include Vaccine production, Recombinant protein production, Study of cancer, Study of gene expression, Cloning, Study of chromosomal and genetic abnormalities.

Vaccine production, Recombinant protein production, Study of cancer, Study of gene expression, Study of chromosomal and genetic abnormalities.

Dr Joël Richard is currently Senior Vice President, Peptides in IPSEN (France). He is globally leading all the pharmaceutical development activities of both injectable and oral peptide-based products, including APIs and drug products, with major franchises in Oncology, Endocrinology and Neurology. Dr Richard has more than 25 years of experience in chemistry and biopharmaceutical R&D, including several previous global senior positions in various Biotech and Pharma companies, such as: - Vice President, Drug Product Development in Ipsen (France) (2008-2011), - Director, Pharmaceutical Development in Serono and Merck Serono (Italy, Germany) (2005-2008), - Vice President Research, and Europe R&D Director at Ethypharm (France) (2001-2004), - COO at Mainelab (France), a drug delivery company he co-founded, which was specialized in developing solvent-free processes for protein delivery systems (1999-2001). Dr Richard graduated from Ecole Normale Supérieure (Cachan, 1985). He has got a PhD in Materials & Colloidal Science (University of Paris VI, 1987) and “Habilitation à Diriger les Recherches” in Chemistry (University of Bordeaux I, 1994).

In the last 20 years, Dr Richard has focused his research activity on new formulation technologies and drug delivery systems (such as microspheres, nanoparticles, nanocapsules, chemically-modified proteins, supercritical fluid technology . . .), especially for injectable peptide and protein formulations. He has published 67 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields: polymers, colloids and interfaces, drug delivery, biodegradable microspheres, microencapsulation, supercritical fluids, protein formulations and post-translational modifications, nanoparticles, sustained-release formulations. He is the author of more than 120 international communications and 53 patent families.

Prof. Dr. Christopher Brown, Ph.D., D.Sc., CC, AOE, FRS is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He is an American analytical and organic chemist, who pioneered a number of discoveries in the field of chemistry, his first and most famous being the synthesis of sucrose. His contributions include the discovery of the anomeric effect and the development of general methodologies for the synthesis of saccharides still employed in the area of Nucleic Acids Chemistry. He was a fellow of the American Chemical Society (ACS) and also the Royal Society of Chemistry (England), and a recipient of the prestigious Albert Einstein World Award of Science and Wolf Prize in Chemistry. Furthermore, he is currently Dean of the Faculty of Chemistry at California South University (CSU), Irvine, California, USA.

Discoveries in the field of chemistry, his first and most famous being the synthesis of sucrose and saccharides